Resmed Inc. · NYSE:RMD
Resmed — Q2 FY2021 Earnings Presentation
17 slides from Resmed's earnings presentation, Jan 28, 2021
Slide 1: Q2 FY2021 Earnings
Q2 FY2021 Earnings January 28, 2021
Slide 2: Presentation of financial information & forward-looking statements
Presentation of financial information & forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepa
Slide 3: Our mission is to change 250 million lives in 2025
Our mission is to change 250 million lives in 2025 We're proud to offer digital and connected health solutions that help those with sleep apnea, COPD, and other respiratory diseases live happier, healthier lives in the comfort of home or care setting of their choice During the last 12 months, we cha
Slide 4: ResMed at a glance
ResMed at a glance KEY STATISTICS1 Revenue by Business Revenue by Region LTM 2Q21 LTM 2Q21 LTM 2Q21 REVENUE $3.1B FOUNDED 1989 Americas 12% 12% Sleep and LISTED (NYSE, ASX) 1995, RMD Devices Respiratory Care MARKET CAP ~$30B 51% Masks & Other 52% Europe, Asia 37% 36% and Other HEADQUARTERS San Diego
Slide 5: ResMed 2025: a patient-centric, digitally-enabled strategy
ResMed 2025: a patient-centric, digitally-enabled strategy 250 million lives improved in out-of-hospital healthcare in 2025! Purpose Empower people to live happier, healthier, and higher quality lives in the comfort of their home Growth Focus Global health epidemics in sleep apnea, COPD, other major
Slide 6: Priorities that guide our daily focus
Priorities that guide our daily focus Our triple aim: I. Slow chronic Grow and differentiate Deliver world-leading Build the world's best disease progression our core sleep apnea, medical devices and software solutions COPD, and asthma digital health technology network for healthcare II. Reduce over
Slide 7: Financial Results
Financial Results
Slide 8: Q2 FY21 financial results
Q2 FY21 financial results Revenue by Business Q2 FY21 12% Devices Revenue ($M) Non-GAAP Operating Non-GAAP EPS FCF ($M) Income ($M) 49% Masks & Other +9% +16% +17% 201% 39% $300.0 $160.0 SaaS $800.0 $254.5 $1.50 $1.41 $140.0 $135.0 $250.0 $736.2 $218.5 $120.0 $1.21 $1.30 $200.0 $100.0 $1.10 $150.0 $
Slide 9: Strong balance sheet and recurring free cash flow
Strong balance sheet and recurring free cash flow Operating Cash Flow ($M) Capital Expenditures ($M) Free Cash Flow ($M) Total debt outstanding $826M $883.9 $787.9 $96.0 Less: Cash & cash equiv. $256M $85.1 $513.8 $62.0 $456.1 $428.7 $394.1 Net Debt $570M Unused borrowing capacity $1,435M LTM 2Q19 L
Slide 10: Track record of strong financial returns for shareholders
Track record of strong financial returns for shareholders Revenue ($B) Non-GAAP Operating Income ($M) Non-GAAP EPS 12% CAGR 17% CAGR 15% CAGR $5.30 $3.1 $973 $1.7 $2.64 $436 LTM 2Q16 LTM 2Q21 LTM 2Q16 LTM 2Q21 LTM 2Q16 LTM 2Q21 Total shareholder return, TSR (NYSE shares as of 12/31/2020): 1-yr 38% |
Slide 11: Capital allocation overview
Capital allocation overview Higher Priority Reinvest in product development for $2.1B Deployed Reinvest for 3-Year History high-return organic growth; 7% of 2020 (through Dec. 31, 2020) Growth revenue invested in R&D 3% Actively evaluate potential acquisitions but 20% Pursue M&A pursue only those th
Slide 12: Driving long-term shareholder value
Driving long-term shareholder value Growth & Innovation Market Dynamics Financial Results • Global leader in digital health for • Underpenetrated markets in sleep • Historical revenue and profit growth sleep and respiratory care and COPD • Recurring revenue • Long-term growth opportunities • Healthc
Slide 13: Contact Investor Relations
Contact Investor Relations Phone: (858) 836-5971 Email: investorrelations@resmed.com Website: investor.resmed.com
Slide 14: Appendix
APPENDIX
Slide 15: Reconciliation of non-GAAP financial measures
Reconciliation of non-GAAP financial measures The measures “non-GAAP gross profit” and “non-GAAP gross margin” excludes amortization expense from acquired intangibles related to cost of sales and are reconciled below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended Six M
Slide 16: Reconciliation of non-GAAP financial measures, cont'd
Reconciliation of non-GAAP financial measures, cont’d The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended Six Months Ended December 31, December 31, December 31, December 31,
Slide 17: Reconciliation of non-GAAP financial measures, cont'd
Reconciliation of non-GAAP financial measures, cont’d The measure “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below: (Unaudited; $ in thousands, except for per share amounts) Three Months Ended S